The Experts below are selected from a list of 501 Experts worldwide ranked by ideXlab platform

Jong Soon Kang - One of the best experts on this subject based on the ideXlab platform.

  • inhibition of atopic dermatitis like skin lesions by topical application of a novel Ceramide Derivative k6pc 9p in nc nga mice
    Experimental Dermatology, 2008
    Co-Authors: Jong Soon Kang, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Won Kee Yoon, Eunyi Moon, Chang Woo Lee
    Abstract:

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly begins in childhood. K6PC-9p (N-(Ethyl dihydrogenphosphate)-2-hexyl-3-oxo-decanamide) is a synthetic Ceramide Derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-staramide), which was known to be effective in atopic patients. In this study, we examined the effect of topical application of K6PC-9p on skin inflammation and AD-like skin lesions in mouse models. K6PC-9p dose-dependently inhibited phorbol ester-induced increase in ear thickness in BALB/c mice. Moreover, topical application of K6PC-9p suppressed dust mite extract-induced AD-like skin lesions in NC/Nga mice. Histopathological analysis revealed that both ear swelling and leucocyte infiltration were suppressed by K6PC-9p treatment. K6PC-9p also suppressed IL-4 and TNF-alpha expression in the ears and mast cell infiltration into the ears in NC/Nga mice. Further study demonstrated that K6PC-9p inhibited ConA-induced IL-4 secretion and LPS-induced macrophage activation. Taken together, our results showed that topical application of K6PC-9p exerts beneficial effects in animal model of skin inflammation and AD, suggesting that K6PC-9p might be a promising topical agent for the treatment of inflammatory skin diseases.

  • Inhibition of skin inflammation and atopic dermatitis by topical application of a novel Ceramide Derivative, K112PC-5, in mice
    Archives of Pharmacal Research, 2008
    Co-Authors: Jong Soon Kang, Chang Woo Lee, Kiho Lee, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Gyoonhee Han
    Abstract:

    PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide) is a synthetic Ceramide and has been known to be effective in atopic and psoriatic patients. K112PC-5 (2-Acetyl-N-(1,3-dihydroxyisopropyl)-tetradecanamide) is a novel Ceramide Derivative of PC-9S. In the present study, we examined the effect of K112PC-5 on macrophage and T lymphocyte function in primary macrophages and splenocytes, respectively, as well as the effect of topical application of K112PC-5 on skin inflammation and atopic dermatitis (AD) in mouse models. K112PC-5 inhibited lipopolysaccharide-induced nitrite generation in mouse peritoneal macrophages in a dose-dependent manner. However, K112PC-5 did not affect concanavalin A-induced proliferation, interleukin (IL)-2 secretion and IL-4 secretion in mouse splenocytes. In addition, K112PC-5 significantly suppressed the increase in phorbol ester-induced ear thickness in BALB/c mice. Further study demonstrated that topical application of K112PC-5 also inhibited AD induced by extracts of dust mites, Dermatophagoides pteronyssinus and Dermatophagoides farinae , in NC/Nga mice. Taken together, these results showed that K112PC-5 exerted an anti-inflammatory effect both in vitro and in vivo and proved to be beneficial in an animal model of AD. Our results suggest that K112PC-5 might be beneficial as a topical agent for the treatment of AD.

  • topical application of a novel Ceramide Derivative k6pc 9 inhibits dust mite extract induced atopic dermatitis like skin lesions in nc nga mice
    International Immunopharmacology, 2007
    Co-Authors: Jong Soon Kang, Kiho Lee, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Won Kee Yoon, Songkyu Park
    Abstract:

    Atopic dermatitis (AD) is a chronic inflammatory skin disease. K6PC-9 (N-Ethanol-2-hexyl-3-oxo-decanamide) is a novel synthetic Ceramide Derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide), which was known to be effective in atopic and psoriatic patients. To investigate the immunomodulatory activity of K6PC-9, we examined the effect of K6PC-9 on T lymphocyte and macrophage function and the effect of topical application of K6PC-9 on skin inflammation and AD-like skin lesions in mouse models. K6PC-9 had no effect on concanavalin A-induced proliferation, interleukin (IL)-2 secretion and IL-4 secretion in mouse splenocytes. In contrast, lipopolysaccharide-induced nitrite generation was potently suppressed by K6PC-9 in mouse peritoneal macrophages. In mouse model of skin inflammation, K6PC-9 inhibited phorbol ester-induced increase in ear thickness and expression of tumor necrosis factor-alpha in the ear of BALB/c mice. Topical application of K6PC-9 also suppressed mite extract-induced AD-like skin lesions in NC/Nga mice. Increase in ear thickness was significantly inhibited by K6PC-9 in this model. K6PC-9 also blocked the infiltration of mast cells and neutrophils into the ear. Further study demonstrated that the mRNA expression of tumor necrosis factor-alpha and adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, was also suppressed by K6PC-9 in the ear of mite extract-treated NC/Nga mice. Taken together, the results presented in this report show that K6PC-9 has an anti-inflammatory potential and exerts beneficial effects in an animal model of AD, indicating that K6PC-9 might be used as a topical agent for the treatment of AD.

Chang Woo Lee - One of the best experts on this subject based on the ideXlab platform.

  • inhibition of atopic dermatitis like skin lesions by topical application of a novel Ceramide Derivative k6pc 9p in nc nga mice
    Experimental Dermatology, 2008
    Co-Authors: Jong Soon Kang, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Won Kee Yoon, Eunyi Moon, Chang Woo Lee
    Abstract:

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly begins in childhood. K6PC-9p (N-(Ethyl dihydrogenphosphate)-2-hexyl-3-oxo-decanamide) is a synthetic Ceramide Derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-staramide), which was known to be effective in atopic patients. In this study, we examined the effect of topical application of K6PC-9p on skin inflammation and AD-like skin lesions in mouse models. K6PC-9p dose-dependently inhibited phorbol ester-induced increase in ear thickness in BALB/c mice. Moreover, topical application of K6PC-9p suppressed dust mite extract-induced AD-like skin lesions in NC/Nga mice. Histopathological analysis revealed that both ear swelling and leucocyte infiltration were suppressed by K6PC-9p treatment. K6PC-9p also suppressed IL-4 and TNF-alpha expression in the ears and mast cell infiltration into the ears in NC/Nga mice. Further study demonstrated that K6PC-9p inhibited ConA-induced IL-4 secretion and LPS-induced macrophage activation. Taken together, our results showed that topical application of K6PC-9p exerts beneficial effects in animal model of skin inflammation and AD, suggesting that K6PC-9p might be a promising topical agent for the treatment of inflammatory skin diseases.

  • Inhibition of skin inflammation and atopic dermatitis by topical application of a novel Ceramide Derivative, K112PC-5, in mice
    Archives of Pharmacal Research, 2008
    Co-Authors: Jong Soon Kang, Chang Woo Lee, Kiho Lee, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Gyoonhee Han
    Abstract:

    PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide) is a synthetic Ceramide and has been known to be effective in atopic and psoriatic patients. K112PC-5 (2-Acetyl-N-(1,3-dihydroxyisopropyl)-tetradecanamide) is a novel Ceramide Derivative of PC-9S. In the present study, we examined the effect of K112PC-5 on macrophage and T lymphocyte function in primary macrophages and splenocytes, respectively, as well as the effect of topical application of K112PC-5 on skin inflammation and atopic dermatitis (AD) in mouse models. K112PC-5 inhibited lipopolysaccharide-induced nitrite generation in mouse peritoneal macrophages in a dose-dependent manner. However, K112PC-5 did not affect concanavalin A-induced proliferation, interleukin (IL)-2 secretion and IL-4 secretion in mouse splenocytes. In addition, K112PC-5 significantly suppressed the increase in phorbol ester-induced ear thickness in BALB/c mice. Further study demonstrated that topical application of K112PC-5 also inhibited AD induced by extracts of dust mites, Dermatophagoides pteronyssinus and Dermatophagoides farinae , in NC/Nga mice. Taken together, these results showed that K112PC-5 exerted an anti-inflammatory effect both in vitro and in vivo and proved to be beneficial in an animal model of AD. Our results suggest that K112PC-5 might be beneficial as a topical agent for the treatment of AD.

Yutaka Mizushima - One of the best experts on this subject based on the ideXlab platform.

  • lipid microsphere preparation of a lipophilic Ceramide Derivative suppresses colony formation in a murine experimental pulmonary metastasis model
    Journal of Drug Targeting, 1999
    Co-Authors: Mitsuko Takenaga, Rie Igarashi, Kayo Matsumoto, Jun Takeuchi, Noboru Mizushima, Toshiaki Nakayama, Y Morizawa, Yutaka Mizushima
    Abstract:

    Ceramide is a well-known regulator of apoptosis and cell growth. In this study, we synthesized lipophilic Ceramide Derivatives to incorporate into lipid microspheres (LM) and their activity was evaluated in vivo. Cera 03, a lipophilic Ceramide Derivative synthesized from membrane-permeable C2-Ceramide, caused potent growth inhibition and DNA fragmentation of Meth A-T tumor cells in vitro. Its potency was similar to that of C2-Ceramide. Both compounds increased the proportion of apoptotic cells. Cera 02, the diacetylated form of natural Ceramide (Cer), also suppressed in vitro cell growth with a similar or higher potency to that of Cer, but both were far less potent than C2-Ceramide and Cera 03. LM containing Cera 03 (Lipo-Cera 03) could not totally prevent metastatic incidence of Meth A-T cells, but reduced pulmonary metastatic nodules in number. Intravenous injection of Lipo-Cera 03 (1 mg/kg of Cera 03) produced about 35% inhibition, while Lipo-Cera 02 had no significant effect. In conclusion, Lipo-Cera 03 may have potential as an antimetastatic drug and may also be a useful tool for researching the role of Ceramides in vivo.

  • lipid microsphere preparation of a lipophilic Ceramide Derivative suppressed the colony formation of murine experimental metastasis
    Drug Delivery System, 1999
    Co-Authors: Mitsuko Takenaga, Rie Igarashi, Kayo Matsumoto, Noboru Mizushima, Toshiaki Nakayama, Yutaka Mizushima
    Abstract:

    Ceramide is well known as a regulator of cell apoptosis and cell growth suppression. In this study, we synthesized more lipophilic Ceramide Derivatives in order to incorporate into lipid microsphere (LM), and their activity was evaluated in vivo. Cera 03, diacetylated form of C2-Ceramide showed a potent cell growth inhibition and potently induced apoptosis in both U 937 cells and Meth A-T tumor cells in vitro, with a similar potency as cell membrane-permeable C2-Ceramide. Diacetylated form of natural type Ceramide (Ger), Cera 02, also suppressed the in vitro cell growth with a similar potency as that of Cer, which was much lower than that of C2-Ceramide and Cera 03. LM preparation of Cera 03 (Lipo-Cera 03, 1 mg/ml) was stable, and inhibited the murine experimental pulmonary metastasis employed with Meth A-T cells. Intravenous injection of lipo-Cera 03 (1 mg/kg of Cera 03) showed over 35% inhibition in the experimental metastasis model. In while, LM preparation of Cera 02 (Lipo-Cera 02, 1 mg/ml) was also stable, however, a significant efficacy was not observed. Therefore, LM emulsion of a Ceramide Derivative (Cera 03) has a potential for an anti-metastatic injectable drug, and also would be an useful tool for researching the role of Ceramide in vivo.

Byeong Deog Park - One of the best experts on this subject based on the ideXlab platform.

  • inhibition of atopic dermatitis like skin lesions by topical application of a novel Ceramide Derivative k6pc 9p in nc nga mice
    Experimental Dermatology, 2008
    Co-Authors: Jong Soon Kang, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Won Kee Yoon, Eunyi Moon, Chang Woo Lee
    Abstract:

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly begins in childhood. K6PC-9p (N-(Ethyl dihydrogenphosphate)-2-hexyl-3-oxo-decanamide) is a synthetic Ceramide Derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-staramide), which was known to be effective in atopic patients. In this study, we examined the effect of topical application of K6PC-9p on skin inflammation and AD-like skin lesions in mouse models. K6PC-9p dose-dependently inhibited phorbol ester-induced increase in ear thickness in BALB/c mice. Moreover, topical application of K6PC-9p suppressed dust mite extract-induced AD-like skin lesions in NC/Nga mice. Histopathological analysis revealed that both ear swelling and leucocyte infiltration were suppressed by K6PC-9p treatment. K6PC-9p also suppressed IL-4 and TNF-alpha expression in the ears and mast cell infiltration into the ears in NC/Nga mice. Further study demonstrated that K6PC-9p inhibited ConA-induced IL-4 secretion and LPS-induced macrophage activation. Taken together, our results showed that topical application of K6PC-9p exerts beneficial effects in animal model of skin inflammation and AD, suggesting that K6PC-9p might be a promising topical agent for the treatment of inflammatory skin diseases.

  • Inhibition of skin inflammation and atopic dermatitis by topical application of a novel Ceramide Derivative, K112PC-5, in mice
    Archives of Pharmacal Research, 2008
    Co-Authors: Jong Soon Kang, Chang Woo Lee, Kiho Lee, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Gyoonhee Han
    Abstract:

    PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide) is a synthetic Ceramide and has been known to be effective in atopic and psoriatic patients. K112PC-5 (2-Acetyl-N-(1,3-dihydroxyisopropyl)-tetradecanamide) is a novel Ceramide Derivative of PC-9S. In the present study, we examined the effect of K112PC-5 on macrophage and T lymphocyte function in primary macrophages and splenocytes, respectively, as well as the effect of topical application of K112PC-5 on skin inflammation and atopic dermatitis (AD) in mouse models. K112PC-5 inhibited lipopolysaccharide-induced nitrite generation in mouse peritoneal macrophages in a dose-dependent manner. However, K112PC-5 did not affect concanavalin A-induced proliferation, interleukin (IL)-2 secretion and IL-4 secretion in mouse splenocytes. In addition, K112PC-5 significantly suppressed the increase in phorbol ester-induced ear thickness in BALB/c mice. Further study demonstrated that topical application of K112PC-5 also inhibited AD induced by extracts of dust mites, Dermatophagoides pteronyssinus and Dermatophagoides farinae , in NC/Nga mice. Taken together, these results showed that K112PC-5 exerted an anti-inflammatory effect both in vitro and in vivo and proved to be beneficial in an animal model of AD. Our results suggest that K112PC-5 might be beneficial as a topical agent for the treatment of AD.

  • topical application of a novel Ceramide Derivative k6pc 9 inhibits dust mite extract induced atopic dermatitis like skin lesions in nc nga mice
    International Immunopharmacology, 2007
    Co-Authors: Jong Soon Kang, Kiho Lee, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Won Kee Yoon, Songkyu Park
    Abstract:

    Atopic dermatitis (AD) is a chronic inflammatory skin disease. K6PC-9 (N-Ethanol-2-hexyl-3-oxo-decanamide) is a novel synthetic Ceramide Derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide), which was known to be effective in atopic and psoriatic patients. To investigate the immunomodulatory activity of K6PC-9, we examined the effect of K6PC-9 on T lymphocyte and macrophage function and the effect of topical application of K6PC-9 on skin inflammation and AD-like skin lesions in mouse models. K6PC-9 had no effect on concanavalin A-induced proliferation, interleukin (IL)-2 secretion and IL-4 secretion in mouse splenocytes. In contrast, lipopolysaccharide-induced nitrite generation was potently suppressed by K6PC-9 in mouse peritoneal macrophages. In mouse model of skin inflammation, K6PC-9 inhibited phorbol ester-induced increase in ear thickness and expression of tumor necrosis factor-alpha in the ear of BALB/c mice. Topical application of K6PC-9 also suppressed mite extract-induced AD-like skin lesions in NC/Nga mice. Increase in ear thickness was significantly inhibited by K6PC-9 in this model. K6PC-9 also blocked the infiltration of mast cells and neutrophils into the ear. Further study demonstrated that the mRNA expression of tumor necrosis factor-alpha and adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, was also suppressed by K6PC-9 in the ear of mite extract-treated NC/Nga mice. Taken together, the results presented in this report show that K6PC-9 has an anti-inflammatory potential and exerts beneficial effects in an animal model of AD, indicating that K6PC-9 might be used as a topical agent for the treatment of AD.

Mi Hwa Han - One of the best experts on this subject based on the ideXlab platform.

  • inhibition of atopic dermatitis like skin lesions by topical application of a novel Ceramide Derivative k6pc 9p in nc nga mice
    Experimental Dermatology, 2008
    Co-Authors: Jong Soon Kang, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Won Kee Yoon, Eunyi Moon, Chang Woo Lee
    Abstract:

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease that commonly begins in childhood. K6PC-9p (N-(Ethyl dihydrogenphosphate)-2-hexyl-3-oxo-decanamide) is a synthetic Ceramide Derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-staramide), which was known to be effective in atopic patients. In this study, we examined the effect of topical application of K6PC-9p on skin inflammation and AD-like skin lesions in mouse models. K6PC-9p dose-dependently inhibited phorbol ester-induced increase in ear thickness in BALB/c mice. Moreover, topical application of K6PC-9p suppressed dust mite extract-induced AD-like skin lesions in NC/Nga mice. Histopathological analysis revealed that both ear swelling and leucocyte infiltration were suppressed by K6PC-9p treatment. K6PC-9p also suppressed IL-4 and TNF-alpha expression in the ears and mast cell infiltration into the ears in NC/Nga mice. Further study demonstrated that K6PC-9p inhibited ConA-induced IL-4 secretion and LPS-induced macrophage activation. Taken together, our results showed that topical application of K6PC-9p exerts beneficial effects in animal model of skin inflammation and AD, suggesting that K6PC-9p might be a promising topical agent for the treatment of inflammatory skin diseases.

  • Inhibition of skin inflammation and atopic dermatitis by topical application of a novel Ceramide Derivative, K112PC-5, in mice
    Archives of Pharmacal Research, 2008
    Co-Authors: Jong Soon Kang, Chang Woo Lee, Kiho Lee, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Gyoonhee Han
    Abstract:

    PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide) is a synthetic Ceramide and has been known to be effective in atopic and psoriatic patients. K112PC-5 (2-Acetyl-N-(1,3-dihydroxyisopropyl)-tetradecanamide) is a novel Ceramide Derivative of PC-9S. In the present study, we examined the effect of K112PC-5 on macrophage and T lymphocyte function in primary macrophages and splenocytes, respectively, as well as the effect of topical application of K112PC-5 on skin inflammation and atopic dermatitis (AD) in mouse models. K112PC-5 inhibited lipopolysaccharide-induced nitrite generation in mouse peritoneal macrophages in a dose-dependent manner. However, K112PC-5 did not affect concanavalin A-induced proliferation, interleukin (IL)-2 secretion and IL-4 secretion in mouse splenocytes. In addition, K112PC-5 significantly suppressed the increase in phorbol ester-induced ear thickness in BALB/c mice. Further study demonstrated that topical application of K112PC-5 also inhibited AD induced by extracts of dust mites, Dermatophagoides pteronyssinus and Dermatophagoides farinae , in NC/Nga mice. Taken together, these results showed that K112PC-5 exerted an anti-inflammatory effect both in vitro and in vivo and proved to be beneficial in an animal model of AD. Our results suggest that K112PC-5 might be beneficial as a topical agent for the treatment of AD.

  • topical application of a novel Ceramide Derivative k6pc 9 inhibits dust mite extract induced atopic dermatitis like skin lesions in nc nga mice
    International Immunopharmacology, 2007
    Co-Authors: Jong Soon Kang, Kiho Lee, Mi Hwa Han, Hyunju Lee, Jong-kyung Youm, Se Kyoo Jeong, Byeong Deog Park, Sang-bae Han, Won Kee Yoon, Songkyu Park
    Abstract:

    Atopic dermatitis (AD) is a chronic inflammatory skin disease. K6PC-9 (N-Ethanol-2-hexyl-3-oxo-decanamide) is a novel synthetic Ceramide Derivative of PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide), which was known to be effective in atopic and psoriatic patients. To investigate the immunomodulatory activity of K6PC-9, we examined the effect of K6PC-9 on T lymphocyte and macrophage function and the effect of topical application of K6PC-9 on skin inflammation and AD-like skin lesions in mouse models. K6PC-9 had no effect on concanavalin A-induced proliferation, interleukin (IL)-2 secretion and IL-4 secretion in mouse splenocytes. In contrast, lipopolysaccharide-induced nitrite generation was potently suppressed by K6PC-9 in mouse peritoneal macrophages. In mouse model of skin inflammation, K6PC-9 inhibited phorbol ester-induced increase in ear thickness and expression of tumor necrosis factor-alpha in the ear of BALB/c mice. Topical application of K6PC-9 also suppressed mite extract-induced AD-like skin lesions in NC/Nga mice. Increase in ear thickness was significantly inhibited by K6PC-9 in this model. K6PC-9 also blocked the infiltration of mast cells and neutrophils into the ear. Further study demonstrated that the mRNA expression of tumor necrosis factor-alpha and adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, was also suppressed by K6PC-9 in the ear of mite extract-treated NC/Nga mice. Taken together, the results presented in this report show that K6PC-9 has an anti-inflammatory potential and exerts beneficial effects in an animal model of AD, indicating that K6PC-9 might be used as a topical agent for the treatment of AD.